Knight Therapeutics Inc. (OTCMKTS:KHTRF) Short Interest Update

Knight Therapeutics Inc. (OTCMKTS:KHTRF) was the target of a large decrease in short interest in the month of June. As of June 15th, there was short interest totaling 317,034 shares, a decrease of 35.2% from the May 31st total of 489,147 shares. Based on an average daily volume of 24,638 shares, the days-to-cover ratio is currently 12.9 days.

Knight Therapeutics Stock Up 1.9%

KHTRF stock opened at $7.09 on Thursday. Knight Therapeutics has a one year low of $4.07 and a one year high of $7.40. The company has a 50 day moving average price of $6.18 and a two-hundred day moving average price of $5.16.

Analyst Ratings Changes

Separately, Royal Bank Of Canada reiterated an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Knight Therapeutics Company Profile

Knight Therapeutics Inc (OTCMKTS:KHTRF) is a specialty pharmaceutical company headquartered in Montreal, Canada, focused on acquiring, in-licensing and commercializing innovative branded products for the Canadian and Latin American markets. The company secures exclusive marketing and distribution rights to medicines across multiple therapeutic areas, including ophthalmology, pain management, hematology and women’s health. Its portfolio features both prescription pharmaceuticals and specialty products that address unmet patient needs through targeted treatments.

Operating primarily in Canada, Mexico and select Latin American countries, Knight has established strategic alliances with global pharmaceutical firms to introduce novel therapies at various stages of development.